Personnel Information

写真a

KANO Yoshihito


Job title

Junior Associate Professor

Laboratory Address

1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan

Laboratory Phone number

+81-3-5803-5391

Laboratory Fax number

+81-3-5803-0416

Mail Address

The inquiry by e-mail is 《here》

Research Areas, Keywords

Medical Oncology, Cancer gnomic medicine, Targeted therapy
To the head of this page.▲

Graduating School 【 display / non-display 】

  • Tokyo Medical and Dental University, Faculty of Medicine, 2005.03, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Tokyo Medical and Dental University, Graduate School, Division of Medical Sciences, Doctor's Course, 2012.03, Completed

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2012.04
    -
    2014.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Gastroenterology and Hepatology， Senior Resident
  • 2016.06
    -
    2017.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Systemic Organ Regulation， Gastroenterology and Hepatology， Visiting Lecturer
  • 2019.04
    -
    2022.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Comprehensive Patient Care， Clinical Oncology， Project Assistant Professor
  • 2022.04
    -
    2024.09
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Comprehensive Patient Care， Clinical Oncology， Junior Associate Professor
  • 2024.10
    -
    Now
    Institute of Science Tokyo， -， Graduate Schools， Comprehensive Patient Care， Department of Clinical Oncology， Junior Associate Professor
To the head of this page.▲

External Career 【 display / non-display 】

  • 2005.04
    -
    2006.03
    , Trainee Resident
  • 2006.04
    -
    2007.03
    , Trainee Resident
  • 2007.04
    -
    2009.03
    , Senior Resident
  • 2014.04
    -
    2019.03
    University of Toronto, Faculty of Medicine, Department of Laboratory Medicine and Pathobiology, Postdoctral Fellow
To the head of this page.▲

Academic Society Affiliations 【 display / non-display 】

  • American Society of Clinical Oncology (ASCO) Active Member

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Genome biology

  • Tumor diagnostics and therapeutics

  • Tumor biology

  • Gastroenterology

  • General internal medicine

  • Molecular biology

▼display all

To the head of this page.▲

Qualification Acquired 【 display / non-display 】

  • Practical English Proficiency Test (1or semi-1 or 2 class)

  • Doctor

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Ogasawara, N; Kano, Y; Yoneyama, Y; Kobayashi, S; Watanabe, S; Kirino, S; Velez-Bravo, FD; Hong, Y; Ostapiuk, A; Lutsik, P; Onishi, I; Yamauchi, S; Hiraguri, Y; Ito, G; Kinugasa, Y; Ohashi, K; Watanabe, M; Okamoto, R; Tejpar, S; Yui, S. Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor lines ISCIENCE. 2024.03; 27 (3): 109247. ( PubMed, DOI )

  2. Naito T, Noji R, Kugimoto T, Kuroshima T, Tomioka H, Fujiwara S, Suenaga M, Harada H, Kano Y. The Efficacy of Immunotherapy and Clinical Utility of Comprehensive Genomic Profiling in Adenoid Cystic Carcinoma of Head and Neck. Medicina (Kaunas, Lithuania). 2023.12; 59 (12): ( PubMed, DOI )

  3. Noji R, Tohyama K, Kugimoto T, Kuroshima T, Hirai H, Tomioka H, Michi Y, Tasaki A, Ohno K, Ariizumi Y, Onishi I, Suenaga M, Mori T, Okamoto R, Yoshimura R, Miura M, Asakage T, Miyake S, Ikeda S, Harada H, Kano Y. Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. Cancers. 2022.07; 14 (14): ( PubMed, DOI )

  4. Gebregiworgis T*, Kano Y* (*contributed equally), St-Germain J, Radulovich N, Udaskin ML, Mentes A, Huang R, Poon BPK, He W, Valencia-Sama I, Robinson CM, Huestis M, Miao J, Yeh JJ, Zhang ZY, Irwin MS, Lee JE, Tsao MS, Raught B, Marshall CB, Ohh M, Ikura M. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature communications. 2021.11; 12 (1): 6274. ( PubMed, DOI )

  5. Yoshihito Kano, Teklab Gebregiworgis, Christopher B Marshall, Nikolina Radulovich, Betty P K Poon, Jonathan St-Germain, Jonathan D Cook, Ivette Valencia-Sama, Benjamin M M Grant, Silvia Gabriela Herrera, Jinmin Miao, Brian Raught, Meredith S Irwin, Jeffrey E Lee, Jen Jen Yeh, Zhong-Yin Zhang, Ming-Sound Tsao, Mitsuhiko Ikura, Michael Ohh. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature communications. 2019.01; 10 (1): 224. ( PubMed, DOI )

  6. Yoshihito Kano, Jonathan D Cook, Jeffrey E Lee, Michael Ohh. New structural and functional insight into the regulation of Ras. Semin. Cell Dev. Biol. 2016.10; 58 70-78. ( PubMed, DOI )

  7. Severa Bunda, Kelly Burrell, Pardeep Heir, Lifan Zeng, Amir Alamsahebpour, Yoshihito Kano, Brian Raught, Zhong-Yin Zhang, Gelareh Zadeh, Michael Ohh. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature Communications. 2015.11; 6 8859. ( PubMed, DOI )

  8. Yoshihito Kano, Kiichiro Tsuchiya, Xiu Zheng, Nobukatsu Horita, Keita Fukushima, Shuji Hibiya, Yuhki Yamauchi, Tatsunori Nishimura, Kunihiko Hinohara, Noriko Gotoh, Shinji Suzuki, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe. The acquisition of malignant potential in colon cancer is regulated by the stabilization of Atonal homolog 1 protein. Biochem. Biophys. Res. Commun.. 2013.03; 432 (1): 175-181. ( PubMed, DOI )

  9. Su Y, Ouchi R, Daroonpan P, Hamagaki M, Ikeda T, Rika N, Nishii N, Tsushima F, Kano Y, Asakage T, Noguchi M, Harada H, Azuma M. Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors. Cancer immunology, immunotherapy : CII. 2025.03; 74 (4): 130. ( PubMed, DOI )

  10. Morikawa, R; Nitta, K; Yasuda, S; Kano, Y; Noji, R; Aoyama, S; Sato, S; Ikeda, S; Okamoto, R; Nagata, M; Mori, T; Suenaga, M. Identification of risk factors for gastrointestinal immune-related adverse events associated with immune check point inhibitors EXPERT OPINION ON DRUG SAFETY. 2024.12; 1-8. ( PubMed, DOI )

  11. Noji R, Tohyama K, Nakamura S, Naito T, Oikawa Y, Kuroshima T, Tomioka H, Michi Y, Ikeda S, Asakage T, Miura M, Hamamoto Y, Harada H, Kano Y. Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study. International journal of molecular sciences. 2024.12; 26 (1): ( PubMed, DOI )

  12. Ito M, Yokoyama K, Ariizumi Y, Kano Y, Yamamoto K, Asakage T, Tateishi U. Desmoid Fibromatosis Involving the Retropharyngeal and Danger Spaces: A Case Report. Cureus. 2024.12; 16 (12): e75969. ( PubMed, DOI )

  13. Suenaga M, Yamauchi S, Morikawa R, Noji R, Kano Y, Tokunaga M, Kinugasa Y. Chemotherapy and COVID-19 Vaccination in Patients With Gastrointestinal Cancer. In vivo (Athens, Greece). 2024.05; 38 (3): 1278-1284. ( PubMed, DOI )

  14. Fujiwara S, Kano Y, Maejima Y, Fujioka T, Tamura K, Kirimura S, Miyake S, Okamoto R. Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab. Internal medicine (Tokyo, Japan). 2023.06; ( PubMed, DOI )

  15. Kaneko S, Asahina Y, Nakagawa M, Murakawa M, Miyazaki Y, Asakage T, Fukuda S, Namiki T, Kano Y, Nagata M, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Itsui Y, Kakinuma S, Okamoto R. Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatology research : the official journal of the Japan Society of Hepatology. 2023.01; 53 (5): 450-459. ( PubMed, DOI )

  16. Kobayashi Sakurako, Ogasawara Nobuhiko, Watanabe Satoshi, Yoneyama Yosuke, Kirino Sakura, Hiraguri Yui, Inoue Masami, Nagata Sayaka, Okamoto-Uchida Yoshimi, Kofuji Satoshi, Shimizu Hiromichi, Ito Go, Mizutani Tomohiro, Yamauchi Shinichi, Kinugasa Yusuke, Kano Yoshihito, Nemoto Yasuhiro, Watanabe Mamoru, Tsuchiya Kiichiro, Nishina Hiroshi, Okamoto Ryuichi, Yui Shiro. コラーゲンI型を介した機械的シグナル伝達は腸炎時の上皮細胞の運命転換を制御する(Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammation) Inflammation and Regeneration. 2022.11; 42 1 of 18-18 of 18. ( ichushi )

  17. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Yamaguchi Takeshi, Watanabe Shun, Nakajima Masanobu, Morita Shinji, Nakamura Takatoshi, Suzuki Kan, Tsuchioka Takashi, Kojima Kazuyuki, Miyake Satoshi, Takagi Masatoshi, Ikeda Sadakatsu. A Pilot Study of Comprehensive Genomic Profiling for Pediatric and Adolescent and Young Adult Solid Tumor Patients in Japan(和訳中) Dokkyo Medical Journal. 2022.03; 1 (1): 56-62. ( ichushi )

  18. Onishi Iichiroh, Kirimura Susumu, Wakejima Ryo, Okubo Kenichi, Odai Tamami, Kakuta Ryota, Kano Yoshihito, Ikeda Sadakatsu, Akashi Takumi, Kitagawa Masanobu. Primary pulmonary choriocarcinoma with a genomic sequence(和訳中) Pathology International. 2022.02; 72 (2): 141-143. ( ichushi )

  19. Aoyagi Y, Kano Y, Tohyama K, Matsudera S, Kumaki Y, Takahashi K, Mitsumura T, Harada Y, Sato A, Nakamura H, Sueoka E, Aragane N, Kimura K, Onishi I, Takemoto A, Akahoshi K, Ono H, Ishikawa T, Tokunaga M, Nakagawa T, Oshima N, Nakamura R, Takagi M, Asakage T, Uetake H, Tanabe M, Miyake S, Kinugasa Y, Ikeda S. Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. PloS one. 2022; 17 (3): e0266112. ( PubMed, DOI )

  20. Noji R, Kano Y*(*corresponding author), Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral oncology. 2021.12; 124 105666. ( PubMed, DOI )

  21. Ikeda Sadakatsu, Kudo Ryo, Yamashita Yamato, Noji Rika, Yokobori Jyunko, Ohki Mika, Takamine Eriko, Kobayashi Yumi, Egawa Makiko, Ebana Yusuke, Kimura Koichiro, Yokoyama Kohta, Onishi Iichiro, Takemoto Akira, Kirimura Susumu, Kinowaki Yuko, Tanimoto Kosuke, Miya Fuyuki, Kano Yoshihito, Yoshida Masayuki, Miyake Satoshi. Clinical utility of multi-disciplinary expert panel discussion in precision cancer medicine ANNALS OF ONCOLOGY. 2021.07; 32 S287. ( DOI )

  22. Kano Yoshihito, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Miyake Satoshi, Ohh Michael. KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor ANNALS OF ONCOLOGY. 2021.07; 32 S306. ( DOI )

  23. Matsudera S, Kano Y, Aoyagi Y, Tohyama K, Takahashi K, Kumaki Y, Mitsumura T, Kimura K, Onishi I, Takemoto A, Ban D, Ono H, Kudo A, Oshima N, Ogino K, Watanabe S, Tani Y, Yamaguchi T, Nakajima M, Morita S, Yamaguchi S, Takagi M, Ishikawa T, Nakagawa T, Okamoto K, Uetake H, Tanabe M, Miyake S, Tsuchioka T, Kojima K, Ikeda S. A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Annals of surgical oncology. 2021.03; ( PubMed, DOI )

  24. Matsudera S, Kano Y, Ikeda S. ASO Author Reflections: Impact of Liquid Biopsy Using Plasma Cell-Free DNA in Solid Tumors in Japan. Annals of surgical oncology. 2021.03; ( PubMed, DOI )

  25. Kano Yoshihito, Marshall Christopher, Ikura Mitsuhiko. Evasion of KRAS Q61H regulation by tyrosine phosphorylation renders cancer cells resistant to SHP2 inhibitors CANCER SCIENCE. 2021.02; 112 171.

  26. Liotti F, Kumar N, Prevete N, Marotta M, Sorriento D, Ieranò C, Ronchi A, Marino FZ, Moretti S, Colella R, Puxeddu E, Paladino S, Kano Y, Ohh M, Scala S, Melillo RM. PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. Journal of experimental & clinical cancer research : CR. 2021.01; 40 (1): 22. ( PubMed, DOI )

  27. Katsukura N, Watanabe S, Shirasaki T, Hibiya S, Kano Y, Akahoshi K, Tanabe M, Kirimura S, Akashi T, Kitagawa M, Okamoto R, Watanabe M, Tsuchiya K. Intestinal phenotype is maintained by Atoh1 in the cancer region of intraductal papillary mucinous neoplasm. Cancer science. 2020.12; ( PubMed, DOI )

  28. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Tsuchioka Takashi, Kojima Kazuyuki, Takagi Masatoshi, Ikeda Sadakatsu. Clinical Utility of Comprehensive Genomic Profiling for Pediatric and AYA Solid Tumor Patients PEDIATRIC BLOOD & CANCER. 2020.12; 67

  29. Aoyagi Yasuko, Kano Yoshihito, Ban Daisuke, Tokunaga Masanori, Nakajima Yasuaki, Uetake Hiroyuki, Tanabe Minoru, Miyake Satoshi, Kinugasa Yusuke, Ikeda Sadakatsu. Future perspectives of cancer genomic medicine in gastroenterological surgery　Clinical utility of multiple genomic testing in patients with advanced solid tumor(和訳中) 日本消化器外科学会総会. 2020.12; 75回 WS14-3. ( ichushi )

  30. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. ドライバー遺伝子異常陽性がん治療の新たな局面　KRASQ61H変異によるSHP2阻害剤耐性機構解析 日本癌学会総会記事. 2020.10; 79回 IS1-3. ( ichushi )

  31. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Tsuchioka Takashi, Kojima Kazuyuki, Takagi Masatoshi, Ikeda Sadakatsu. 小児・AYA世代の進行再発固形がん患者におけるがん遺伝子パネル検査の臨床的有用性の検討(Clinical utility of comprehensive genomic profiling for pediatric and AYA solid tumor patients) 日本小児血液・がん学会雑誌. 2020.10; 57 (4): 243. ( ichushi )

  32. 松寺 翔太郎, 加納 嘉人, 青柳 康子, 遠山 皓基, 木村 浩一朗, 大西 威一郎, 竹本 暁, 荻野 恵, 岡本 健太郎, 植竹 宏之, 田邉 稔, 三宅 智, 土岡 丘, 小嶋 一幸, 池田 貞勝. Liquid biopsyが変えるがん治療　がんゲノム医療におけるリキッドバイオプシーの臨床的有用性の検討 日本癌治療学会学術集会抄録集. 2020.10; 58回 WS12-4. ( ichushi )

  33. Ivette Valencia-Sama, Yagnesh Ladumor, Lynn Kee, Teresa Adderley, Gabriella Christopher, Claire M Robinson, Yoshihito Kano, Michael Ohh, Meredith S Irwin. Status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma. Cancer Res. 2020.08; 80 (16): 3413-3423. ( PubMed, DOI )

  34. Takahashi Kenta, Gen Yasuyuki, Tanimoto Kousuke, Kudo Atsushi, Oshima Noriko, Ban Daisuke, Takemoto Akira, Onishi Iichiro, Kumaki Yuichi, Yokobori Junko, Takamine Eriko, Kano Yoshihito, Miyake Satoshi, Miyasaka Naoyuki, Tanabe Minoru, Inazawa Johji, Ikeda Sadakatsu. Clinical impact of hemizygous deletion detection and panel-size in comprehensive genomic profiling. JOURNAL OF CLINICAL ONCOLOGY. 2020.05; 38 (15):

  35. Kitaoka Y, Watanabe D, Nonaka Y, Yagishita K, Kano Y, Hoshino D. Effects of clenbuterol administration on mitochondrial morphology and its regulatory proteins in rat skeletal muscle. Physiological reports. 2019.10; 7 (19): e14266. ( PubMed, DOI )

  36. Claire M Robinson, Betty P K Poon, Yoshihito Kano, Fred G Pluthero, Walter H A Kahr, Michael Ohh. A hypoxia-inducible HIF1-GAL3ST1-sulfatide axis enhances ccRCC immune evasion via increased tumor cell-platelet binding. Mol Cancer Res. 2019.08; 17 (11): 2306-2317. ( PubMed, DOI )

  37. Keita Fukushima, Kiichiro Tsuchiya, Yoshihito Kano, Nobukatsu Horita, Shuji Hibiya, Ryohei Hayashi, Keisuke Kitagaki, Mariko Negi, Eisaku Itoh, Takumi Akashi, Yoshinobu Eishi, Shigeru Oshima, Takashi Nagaishi, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe. Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Science. 2015.08; 106 (8): 1000-1007. ( PubMed, DOI )

  38. Fukushima Keita, Tsuchiya Kiichiro, Kano Yoshihito, Horita Nobukatsu, Hibiya Shuji, Hayashi Ryohei, Kitagaki Keisuke, Negi Mariko, Itoh Eisaku, Akashi Takumi, Eishi Yoshinobu, Oshima Shigeru, Nagaishi Takashi, Okamoto Ryuichi, Nakamura Tetsuya, Watanabe Mamoru. 腫瘍壊死因子αにより安定化するatonal homolog 1タンパク質は大腸癌細胞株において高悪性度を引き起こす(Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line) Cancer Science. 2015.08; 106 (8): 1000-1007. ( ichushi )

  39. Nobukatsu Horita, Kiichiro Tsuchiya, Ryohei Hayashi, Keita Fukushima, Shuji Hibiya, Masayoshi Fukuda, Yoshihito Kano, Tomohiro Mizutani, Yasuhiro Nemoto, Shiro Yui, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe. Fluorescent labelling of intestinal epithelial cells reveals independent long-lived intestinal stem cells in a crypt. Biochem. Biophys. Res. Commun.. 2014.11; 454 (4): 493-499. ( PubMed, DOI )

  40. Yoshihito Kano, Sei Kakinuma, Fumio Goto, Seishin Azuma, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Mina Nakagawa, Atsushi Kudo, Minoru Tanabe, Susumu Kirimura, Tomonori Amano, Takashi Ito, Takumi Akashi, Yasuhiro Asahina, Mamoru Watanabe. Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. Clin J Gastroenterol. 2014.10; 7 (5): 449-454. ( PubMed, DOI )

  41. Kano Yoshihito, Kakinuma Sei, Goto Fumio, Azuma Seishin, Nishimura-Sakurai Yuki, Itsui Yasuhiro, Nakagawa Mina, Kudo Atsushi, Tanabe Minoru, Kirimura Susumu, Amano Tomonori, Ito Takashi, Akashi Takumi, Asahina Yasuhiro, Watanabe Mamoru. 結節の一つに胆管細胞癌部分を合併した原発性肝神経内分泌癌(Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule) Clinical Journal of Gastroenterology. 2014.10; 7 (5): 449-454. ( ichushi )

  42. Severa Bunda, Pardeep Heir, Tharan Srikumar, Jonathan D Cook, Kelly Burrell, Yoshihito Kano, Jeffrey E Lee, Gelareh Zadeh, Brian Raught, Michael Ohh. Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. Proc. Natl. Acad. Sci. U.S.A.. 2014.09; 111 (36): E3785-E3794. ( PubMed, DOI )

  43. Tatsuro Murano, Ryuichi Okamoto, Go Ito, Toru Nakata, Shuji Hibiya, Hiromichi Shimizu, Satoru Fujii, Yoshihito Kano, Tomohiro Mizutani, Shiro Yui, Junko Akiyama-Morio, Yasuhiro Nemoto, Kiichiro Tsuchiya, Tetsuya Nakamura, Mamoru Watanabe. Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. Biochem. Biophys. Res. Commun.. 2014.01; 443 (3): 840-846. ( PubMed, DOI )

  44. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白安定による癌幹細胞形質獲得とニッチ形成(Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer) 日本癌学会総会記事. 2013.10; 72回 137. ( ichushi )

  45. Fukushima Keita, Tsuchiya Kiichiro, Kano Yoshihito, Hibiya Shuji, Horita Nobukatsu, Zheng Xiu, Okamoto Ryuichi, Nakamura Tetsuya, Mamoru Watanabe. 結腸癌においてTNF-αによりAtoh1タンパク質の安定化は癌stemnessを獲得する(Stabilization of Atoh1 Protein by TNF-α in Colon Cancer Acquires Cancer Stemness) 日本消化器病学会雑誌. 2013.02; 110 (臨増総会): A467. ( ichushi )

  46. Kano Y., Tsuchiya K., Watanabe M.. NEW CLASSIFICATION BASED ON ATOH1 EXPRESSION IN COLON CANCER MIGHT BE USEFUL AS BIOMARKER ANNALS OF ONCOLOGY. 2012.10; 23 119.

  47. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh 1蛋白安定による癌幹細胞形質獲得機構解析(The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization) 日本癌学会総会記事. 2012.08; 71回 243-244. ( ichushi )

  48. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 炎症関連大腸癌におけるAtoh1蛋白安定はがん幹細胞形質と抗がん剤耐性を獲得する(The stabilization of Atoh1 protein in colitic cancer induces cancer stemness and chemoresistance) 日本癌学会総会記事. 2012.08; 71回 98. ( ichushi )

  49. Xiu Zheng, Kiichiro Tsuchiya, Ryuichi Okamoto, Michiko Iwasaki, Yoshihito Kano, Naoya Sakamoto, Tetsuya Nakamura, Mamoru Watanabe. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm. Bowel Dis.. 2011.11; 17 (11): 2251-2260. ( PubMed, DOI )

  50. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 大腸癌におけるAtoh1蛋白安定は粘液癌の形質を模倣する(The stabilization of Atoh1 protein in colorectal cancer mimics mucinous adenocarcinoma) 日本癌学会総会記事. 2011.09; 70回 227. ( ichushi )

  51. 加納 嘉人, 土屋 輝一郎, 渡辺 守. 大腸癌におけるAtoh1蛋白安定発現は分化形質だけでなく癌悪性形質を誘導する(Atoh1 protein stabilization in colorectal cancer promotes not only the differentiation but also the malignancy) 日本癌学会総会記事. 2011.09; 70回 338. ( ichushi )

  52. Michiko Iwasaki, Kiichiro Tsuchiya, Ryuichi Okamoto, Xiu Zheng, Yoshihito Kano, Eiko Okamoto, Eriko Okada, Akihiro Araki, Shinji Suzuki, Naoya Sakamoto, Keisuke Kitagaki, Takumi Akashi, Yoshinobu Eishi, Tetsuya Nakamura, Mamoru Watanabe. Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4. J. Gastroenterol.. 2011.02; 46 (2): 191-202. ( PubMed, DOI )

  53. Iwasaki Michiko, Tsuchiya Kiichiro, Okamoto Ryuichi, Zheng Xiu, Kano Yoshihito, Okamoto Eiko, Okada Eriko, Araki Akihiro, Suzuki Shinji, Sakamoto Naoya, Kitagaki Keisuke, Akashi Takumi, Eishi Yoshinobu, Nakamura Tetsuya, Watanabe Mamoru. ヒト全小腸における長軸方向の細胞形成はHath1およびKlf4の局在と相関する(Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4) Journal of Gastroenterology. 2011.02; 46 (2): 191-202. ( ichushi )

  54. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白可視化による未分化大腸がん分化誘導機構解析(The induction of the differentiation of colorectal cancer cells indicated by the visualization of Atoh1 protein) 日本癌学会総会記事. 2010.08; 69回 256. ( ichushi )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Yoshihito Kano, Rika Noji, Takahiro Naito, Sadakatsu Ikeda, Hiroyuki Harada, Yasuo Hamamoto. Clinical Utility of Liquid Biopsy in HNSCC: Insights from the SHIZUKU-HN Study and C-CAT Data . 第22回日本臨床腫瘍学会学術集会 2025.03.06 神戸

  2. Yoshihito Kano, Rika Noji, Kohki Tohyama, Takahiro Naito, Takuma Kugimoto, Takeshi Kuroshima, Hirofumi Tomioka, Yasuyuki Michi, Shun Fujiwara, Mitsukuni Suenaga, Shin Nakamura, Masahiko Miura, Hiroyuki Harada, Yasuo Hamamoto. Image Assessment and ctDNA Analysis in Evaluating Tumor Burden in Head and Neck Cancer Treated with ICIs. 第83回⽇本癌学会学術総会 2024.09.20

  3. Yoshihito Kano. Impact of RAS Mutations on YAP-Driven Chemoresistance in Colorectal Cancer Organoids Cultured in Specific ECM Environments. The 8th JCA-AACR Special Joint Conference 2024.06.28

  4. Yoshihito Kano. Prospective monitoring for immunotherapy by liquid biopsy and signal pathway alterations in head and neck cancers.. ASCO 2024 2024.06.01 Chicago

  5. 松寺 翔太郎, 加納 嘉人, 岡本 健太郎, 鈴木 完, 小嶋 一幸, 三宅 智, 池田 貞勝. がんゲノム医療推進のためのがんプレシジョンメディシンフェローシッププログラム. 日本癌治療学会学術集会抄録集 2021.10.01

  6. YOSHIHITO KANO, Teklab Gebregiworgis, Christopher Marshall, Mitsuhiko Ikura, Satoshi Miyake, Michael Ohh. KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor. 第18回日本臨床腫瘍学会学術集会 2021.02.20

  7. 加納 嘉人,野地 理夏, 山下 大和, 工藤 亮, 田崎 彰久, 大野 十央, 有泉 陽介, 平井 秀明, 富岡 寛文, 島本 裕彰, 道 泰之, 三浦 雅彦, 吉村 亮一, 朝蔭 孝宏, 原田 浩之, 岡本 隆一, 三宅 智, 池田 貞勝. Clinical utility of tumor-profiling multiplex gene panel testing in advanced head and neck cancer at TMDU. 第18回日本臨床腫瘍学会学術集会 2021.02.18

  8. 加納嘉人、野地理夏、山下大和、工藤亮、大西威一郎、谷本幸介、宮冬樹、中川剛士、石川敏昭、植竹宏之、絹笠祐介、田邉稔、朝蔭孝宏、原田浩之、岡本隆一、三宅智、池田貞勝. Detection of RAS mutation in solid cancers using NGS-based genome profiling tests. 第18回日本臨床腫瘍学会学術集会 2021.02.18

  9. Aoyagi Yasuko, Kano Yoshihito, Ban Daisuke, Tokunaga Masanori, Nakajima Yasuaki, Uetake Hiroyuki, Tanabe Minoru, Miyake Satoshi, Kinugasa Yusuke, Ikeda Sadakatsu. 消化器外科とゲノム医療の将来展望　進行性固形腫瘍患者における包括的ゲノムプロファイリングの臨床的有用性(Future perspectives of cancer genomic medicine in gastroenterological surgery　Clinical utility of multiple genomic testing in patients with advanced solid tumor). 日本消化器外科学会総会 2020.12.01

  10. Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Mitsuhiko Ikura, Michael Ohh. Evasion of KRASQ61H regulation by tyrosine phosphorylation renders cancer cells resistant to SHP2 inhibitor. 第79回日本癌学会学術総会 2020.10.01 Hiroshima

  11. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. ドライバー遺伝子異常陽性がん治療の新たな局面　KRASQ61H変異によるSHP2阻害剤耐性機構解析. 日本癌学会総会記事 2020.10.01

  12. Yoshihito Kano, Teklab Gebregiworgis, Christopher Marshall,Mitsuhiko Ikura, Michael Ohh. Inhibition of SHP2 promotes the tyrosyl phosphorylation of KRAS and suppresses the pancreatic cancer growth. 第78回日本癌学会学術集会 2019.09.28 京都

  13. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. チロシンリン酸化モデルに基づくKRAS変異膵癌に対する治療戦略(Inhibition of SHP2 promotes the tyrosyl phosphorylation of KRAS and suppresses the pancreatic cancer growth). 日本癌学会総会記事 2019.09.01

  14. 加納嘉人,Teklab Gebregiworgis, Christopher Marshall, 伊倉 光彦, Michael Ohh. KRASチロシンリン酸化モデルに基づく膵癌新規分子機構と治療戦略. 第17回日本臨床腫瘍学会学術集会 2019.07.18

  15. Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Nikolina Radulovich, Betty P.K. Poon, Zhong-Yin Zhang, Ming-Sound Tsao, Mitsuhiko Ikura and Michael Ohh. TYROSYL PHOSPHORYLATION OF KRAS DISRUPTS THE GTPASE CYCLE AND INHIBITS PANCREATIC CANCER CELL GROWTH.. DDW2018 2018.06.05

  16. Teklab Gebregiworgis, Christopher B. Marshall, Yoshihito Kano, Nikolina Radulovich, Ming-Sound Tsao, Michael Ohh, Mitsuhiko Ikura. Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer. . AACR 2018 2018.04.17

  17. Kano Y. Tyrosyl phosphorylation of KRAS disrupts the GTPase cycle and inhibits pancreatic cancer cell growth. Pizza Talk of Department of Biochemistry 2018.03.21 Toronto(Canada)

  18. Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon B P.K. , Zhang Z, Tsao M, Ikura M, Ohh M. Tyrosyl phosphorylation of KRAS disrupts the GTPase cycle and inhibits pancreatic cancer cell growth. . The Terry Fox Research Institute Ontario Node Research Symposium 2017.12.04 Toronto(Canada)

  19. Kano Y, Poon P.K. B, Radulovich N, Zhang Z, Tsao M, Ohh M. Novel treatment strategy for pancreatic cancer by targeting SHP2-mediated dephosphorylation of KRAS oncoprotein. The 4th Canadian Cancer Research Conference 2017.11.06 Vancouver(Canada)

  20. Kano Y. Poster Judge. 20th Annual LMP Graduate Research Conference 2017.04.13 Toronto(Canada)

  21. 8. Keita Fukushima, Kiichiro Tsuchiya, Shuji Hibiya, Ryohei Hayashi, Nobukatsu Horita, Yoshihito Kano, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe.. Atoh1 Protein Expression by TNF-a and the Acquisition of Malignant Potential in Colitis- Associated Colorectal Cancer. . DDW 2015 2015.05.17

  22. 9. Shuji Hibiya, Kiichiro Tsuchiya, Keita Fukushima, Ryohei Hayashi, Nobukatsu Horita, Yoshihito Kano, Ryuichi Okamoto, Tetsuya Nakamura,Mamoru Watanabe. Continuous stimulation with cytokines leads to irreversible accumulation of NF-κB signaling in colonic epithelial cells.. The 5th International Symposium on Carcinogenic Spiral 2015.02.26

  23. 11. Horita N, Tsuchiya K, Hayashi R, Fukushima K, Hibiya S, Fukuda M, Kano Y, Mizutani T, Nemoto Y, Yui S, Okamoto R, Nakamura T, Watanabe M. Establishment of the gene transduction into the primary intestinal organoid identified the subpopulation of the stem cells in a crypt.. 第12回幹細胞シンポジウム 2014.05.31

  24. 12. Hibiya S, Tsuchiya K, Fukushima K, Hayashi R, Horita N, Kano Y, Okamoto R, Nakamura T, Watanabe M.. Long-term stimulation with cytokines acquires irreversible accumulation of NF-κB signaling in primary colonic epithelial cells. . 4th International Symposium on Carcinogenic Spiral 2014.02.11

  25. 15. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer.. 第72回日本癌学会総会 2013.10.03

  26. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白安定による癌幹細胞形質獲得とニッチ形成(Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer). 日本癌学会総会記事 2013.10.01

  27. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer. . GI Research Academy 2013 2013.06.05

  28. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh 1蛋白安定による癌幹細胞形質獲得機構解析(The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization). 日本癌学会総会記事 2012.08.01

  29. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 炎症関連大腸癌におけるAtoh1蛋白安定はがん幹細胞形質と抗がん剤耐性を獲得する(The stabilization of Atoh1 protein in colitic cancer induces cancer stemness and chemoresistance). 日本癌学会総会記事 2012.08.01

  30. 20. 加納 嘉人, 土屋 輝一郎, 渡辺 守.. NEW CLASSIFICATION BASED ON ATOH1 EXPRESSION IN COLON CANCER MIGHT BE USEFUL AS BIOMARKER.. 第10回日本臨床腫瘍学会学術総会 2012.07.26

  31. 21. Kano Y, Tsuchiya K, Zheng X, Horita N, Okamoto R, Nakamura T, Watanabe M.. The acquisition of cancer stemness in colon cancer by the Atoh1 protein stabilization. International Society for Stem Cell Research 2012 2012.06.14

  32. 22. Tsuchiya K, Zheng X, Kano Y, Horita N, Okamoto R, Nakamura T, Watanabe M.. Flagellin Response via TLR5 on Basolateral Membrane of Primary Intestinal Epithelial Cells is Regulated by Notch Signaling. . DDW2012 2012.05.22

  33. 23. Kano Y, Tsuchiya K, Zheng X, Horita N, Okamoto R, Nakamura T, Watanabe M. . The acquisition of cancer stemness in colon cancer by the Atoh1 protein stabilization.. DDW2012 2012.05.19

  34. 26. Kano Y, Tsuchiya K, Zheng X, Horita N, Okamoto R, Nakamura T, Watanabe M. The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization.. 1st GDRI France-Japan Cancer Meeting 2011.11.23

  35. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 大腸癌におけるAtoh1蛋白安定は粘液癌の形質を模倣する(The stabilization of Atoh1 protein in colorectal cancer mimics mucinous adenocarcinoma). 日本癌学会総会記事 2011.09.01

  36. 加納 嘉人, 土屋 輝一郎, 渡辺 守. 大腸癌におけるAtoh1蛋白安定発現は分化形質だけでなく癌悪性形質を誘導する(Atoh1 protein stabilization in colorectal cancer promotes not only the differentiation but also the malignancy). 日本癌学会総会記事 2011.09.01

  37. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白可視化による未分化大腸がん分化誘導機構解析(The induction of the differentiation of colorectal cancer cells indicated by the visualization of Atoh1 protein). 日本癌学会総会記事 2010.08.01

▼display all

To the head of this page.▲